The biopharmaceuticals giant and drugmaker want to create a leader across immunology, neuroscience, eye care, and other medical fields.

After stirring up a tribal licensing controversy, Allergan has run into a patent setback with big-selling eye medication Restasis. A federal judge invalidated exclusive protections for the ...

Shares of Allergan plc AGN have risen 19.1% this year so far against the industry’s decline of 10.9%. AbbVie ABBV offered to buy Allergan in a cash-and-stock deal worth nearly $63 billion in June, ...

Judges in Amsterdam have rejected a claim for collective damages against pharmaceutical company Allergan, now part of AbbVie, over the health risks linked to its textured breast implants. The case was ...

Allergan plc AGN announced that it has signed a definitive agreement to acquire LifeCell, the regenerative medicine unit of Texas-based privately held company Acelity for $2.9 billion in cash.

There has been a lot of discussion about my views about pharmaceutical research and development. Let me cut to the chase. I'm pro-R&D, but I don't believe that any single company can corner the market ...

Allergan Aesthetics launched its SkinMedica Even & Correct Collection Tuesday morning, featuring a suite of products targeting hyperpigmentation. The company noted that these SkinMedica offerings are ...

Allergan's plan to grow its Botox and fillers businesses relies in large part on getting millennials to use its products. The drug company is launching a handful of millennial-focused campaigns ...

Much of Wall Street greeted hedge fund billionaire Bill Ackman’s announcement that he was teaming up with Valeant Pharmaceuticals to buy Botox-maker Allergan with a mixture of amazement and envy. Some ...

AbbVie said Tuesday it will acquire Allergan for $63 billion — the latest megamerger between two pharma giants seeking new ways to grow. The deal, combining two firms built by past acquisitions, ...

Actavis (ACT) announced Monday that it will buy its pharmaceutical peer Allergan (AGN) in a $66 billion deal that appears to have finally thwarted efforts by Valeant Pharmaceuticals (VRX) to acquire ...

When the maker of the top-selling arthritis drug says it’s buying a leader in anti-wrinkle treatments, you’d be forgiven if your initial response to the news was that it seems like a match made in ...